Participated · Series B · Aug 2026

QuantHealth offers an AI-driven clinical trial simulation platform that enables life sciences companies to evaluate, optimize, and de-risk clinical and commercial decisions before enrolling patients or committing capital. The company serves pharmaceutical and biotechnology organizations and is led by CEO Orr Inbar. QuantHealth is based in Tel Aviv, Israel. Following its Series B, the company plans to scale enterprise-wide impact, accelerate adoption of simulation-first clinical development, advance R&D capabilities, grow its workforce, and expand its product portfolio. The article does not disclose revenues, user counts, or prior funding rounds.

Participated · Series A · Dec 2025

Founded in 2021, Denver-based Lin Health offers a physician-led, coach-supported virtual program that retrains maladaptive pain circuits through therapies such as Pain Reprocessing Therapy, Emotional Awareness and Expression Therapy, and Cognitive Behavioral Therapy. The platform combines proprietary software, AI, and a collaborative care model to engage patients multiple times per week without adding administrative burden. Lin partners with health systems, clinics, and payers and is already accessible to more than 60 million covered Americans. Its solution targets chronic conditions including migraines, IBS, back pain, and joint pain, addressing a $635 billion annual cost burden in the U.S. healthcare system. The company emphasizes value-based outcomes, reduced provider burnout, and lower total cost of care. With fresh Series A capital, Lin plans to accelerate product innovation, scale go-to-market efforts, and deepen clinically integrated partnerships. The oversubscribed funding signals strong investor confidence in Lin’s ability to become the first-line solution for chronic pain nationwide.

Participated · Equity · Oct 2024

FeelBetter has developed an AI-based Pharmaco-Clinical Intelligence platform with four core tools: Insight (risk stratification), Navigator (workflow management), Action (AI decision-support for pharmacists) and Impact (post-intervention monitoring). The company reports reaching more than 300,000 patients daily and cites partnerships with Leumit HMO, Atlantic Health, and a retrospective study at Brigham & Women’s Hospital validating its outcomes. Published and partner-reported results include large reductions in hospital admissions and days, clinical improvements in LDL and HbA1c, a 5x increase in pharmacist capacity reported by Leumit, and estimated cost savings per high-risk patient. FeelBetter has raised $11.5 million from grants and investors to date and is actively seeking Series A funding. The firm says it is expanding its global footprint and plans to partner with more U.S.-based health systems to pursue broader adoption of its population- and individual-level solution.

Led · Seed · May 2024

AISAP offers a POCAD™ solution that applies deep-learning AI to medical ultrasound, delivering automated diagnoses and specialized analyses such as valve-level cardiovascular assessments. The product provides an urgency score to help providers prioritize cases and a scan-quality score to ensure accuracy for operators less familiar with traditional ultrasound devices. Its deep-learning models are designed to yield accurate readings even from lower-quality images produced by handheld machines. The company reports its algorithms were trained on more than 300,000 studies comprising over 24 million video clips, and the technology has been validated by medical experts at The Mayo Clinic, Inova Health Foundation, Jefferson Health, Poriya Institute and others. AISAP plans to use the new funding to expand operations and accelerate development efforts. Leadership includes CEO Roni Attali and cofounders Adiel Am-Shalom, Ehud Raanani, Robert Klempfner and Ehud Schwammenthal.

Led · Equity · Aug 2023

FeelBetter offers a SaaS-based Pharmaco-Clinical Intelligence platform that synthesizes and analyzes healthcare data from multiple sources to pinpoint patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management. The platform proactively suggests immediate, actionable interventions to reduce polypharmacy risks. It also aids healthcare providers in monitoring patients’ progress and measuring the impact of clinical interventions. By using FeelBetter, provider organizations can allocate resources to serve patients and minimize preventable, costly use of healthcare services. The company is led by CEO and co-founder Liat Primor and CTO/COO and co-founder Yoram Hordan, and is based in Boston, MA and Tel Aviv, Israel. Financially, the company raised $5.9M in the latest round, bringing total funding to $8M.